Cerus Corporation (NASDAQ: CERS) is sight a surge after announcing that the land regulatory body titled Swissmedic has approved the ingest of platelet components aerated with Cerus’ INTERCEPT Blood System. The company noted that this support extends permissible hardware instance for platelets to heptad days with INTERCEPT treatment, compared to five days without treatment. Be advised that the land market is a small market, but is also a key to other market. Cerus shares at 8:48 AM EST have already traded 150,000 shares and the terminal change was up over 30% at $2.35. Average volume is about 370,000 shares and the market cap was only $58 million as of the close yesterday. The 52-week high here is $5,02, so this one is not off its charts. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment